Received Sep 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 1 | Unknown | IM |
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | FC3184 | LA |
Injection site pain; immunocompromised patient who received the 1st and 2nd dose of the Moderna COVID 19 vaccine was given Pfizer as the 3rd dose; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE PAIN (Injection site pain) and INTERCHANGE OF VACCINE PRODUCTS (immunocompromised patient who received the 1st and 2nd dose of the Moderna COVID 19 vaccine was given Pfizer as the 3rd dose) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. Unknown and Unknown) for COVID-19 vaccination. Co-suspect product included non-company product Tozinameran (Pfizer BioNTech COVID-19 vaccine) for an unknown indication. Concurrent medical conditions included Immunocompromised. In February 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) dosage was changed to 1 dosage form. On 22-Sep-2021, the patient received third dose of Tozinameran (Pfizer BioNTech COVID-19 vaccine) (unknown route) 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) 1 dosage form. On 22-Sep-2021, the patient experienced VACCINATION SITE PAIN (Injection site pain) and INTERCHANGE OF VACCINE PRODUCTS (immunocompromised patient who received the 1st and 2nd dose of the Moderna COVID 19 vaccine was given Pfizer as the 3rd dose). At the time of the report, VACCINATION SITE PAIN (Injection site pain) and INTERCHANGE OF VACCINE PRODUCTS (immunocompromised patient who received the 1st and 2nd dose of the Moderna COVID 19 vaccine was given Pfizer as the 3rd dose) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use), the reporter did not provide any causality assessments. Most recent FOLLOW-UP information incorporated above includes: On 22-Sep-2021: Upon internal review the case was reassessed and determined to be valid, hence significant correction was performed on 29-Aug-2025.
Immunocompromised